The identification of novel small molecules that can promote the activity of FOXO3 in TNBC cells can provide leads for new TNBC therapeutics against malignant breast tumors in which the PI3K/Akt and/or IKK/NF-kB signaling pathways are aberrantly activated, and these molecules may also result in safe and effective targeted therapy of TNBC. This evidence concerns the gene FOXO3 and breast cancer.